Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lanreotide plus best supportive care versus placebo plus best supportive care in metastatic or unresectable lung neuroendocrine tumors
2015-004992-62Phase 3Completed
- Sponsor
- Ipsen
- Start
- Mar 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lanreotide and Placebo-COD Research Private Ltd in bronchial neuroendocrine tumor (2 arms), sponsored by Ipsen. Primary endpoint: Progression-free survival. Started Mar 2016; status: completed.
02
Drugs
lanreotidePlacebo-COD Research Private Ltd
03
Conditions
bronchial neuroendocrine tumor
Beyond the preview
Go deeper on 2015-004992-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004992-62.